B-lymphoblastic leukemia/lymphoma MLL rearranged is a type of cancer that affects blood cells. This condition is defined by the presence of abnormal lymphoblasts (immature white blood cells) that have a specific genetic change involving the KMT2A gene. In these cells, the KMT2A gene, which is normally found at a particular location on chromosome 11 (11q23.3), becomes fused with another gene partner. This fusion results in the production of an abnormal protein, known as a KMT2A fusion protein, which plays a role in the development and progression of the disease. This genetic abnormality distinguishes the disease and helps to understand its behavior. The abnormal fusion protein disrupts normal blood cell development and leads to the uncontrolled growth of lymphoblasts. Although the exact symptoms and progression can vary, the genetic findings are central to understanding the condition.

Information about symptoms is currently limited for this condition.

The condition is caused by a specific genetic change. The lymphoblasts in people with this disease carry a translocation between the KMT2A gene on chromosome 11q23.3 and another gene partner. This translocation leads to the creation of a KMT2A fusion protein, which is central to the development of the disease. Detailed information about additional risk factors is currently limited.